Eggermont, Alexander M. M.
Robert, Caroline
Ribas, Antoni
Article History
First Online: 30 May 2018
Competing interests
: A.M.M.E. has received consulting and/or advisory board fees from Actelion, Agenus, Bayer, Bristol-Myers Squibb (BMS), Ellipses, GlaxoSmithKline (GSK), HalioDX, Incyte, MedImmune, Merck, Sharp & Dohme (MSD), Merck-Serono, Nektar, Novartis, Pfizer, and Sanofi. C.R. has received consulting and/or advisory board fees from Amgen, BMS, GSK, Merck, Novartis, and Roche. A.R. has received consulting and/or advisory board fees from Amgen, BMS, Chugai, Genentech, Merck, Novartis, and Roche and is on the scientific advisory board of Arcus, BioncoTech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Lutris, Programme of Action for Cancer Therapy (PACT), Rgenix, and Tango.